Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342214 | 0.79 | CCR9 (0.65) | CCR9LMNAPOLB | |
| SCHEMBL10252235 | 0.74 | L3MBTL1 (0.42) | GAARAB9ALTA4HKDM4ELMNA | |
| SCHEMBL11938245 | 0.70 | CCR9 (0.65) | CCR9 | |
| SCHEMBL11303651 | 0.69 | SRD5A2 (0.66) | CCR9RAB9ALTA4HSRD5A2LMNA | |
| SCHEMBL11938257 | 0.69 | CCR9 (0.53) | CCR9 | |
| SCHEMBL14034474 | 0.69 | CCR9 (0.53) | CCR9 | |
| SCHEMBL11937175 | 0.68 | CCR9 (0.55) | CCR9LMNA | |
| SCHEMBL343825 | 0.67 | ALDH1A1 (0.54) | CCR9POLB | |
| SCHEMBL11936670 | 0.67 | CCR9 (0.48) | CCR9LMNA | |
| SCHEMBL14034607 | 0.67 | CCR9 (0.50) | CCR9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270616-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270616-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885GAA 2519/4885RAB9A 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.